VC fund profile · evidence-aware directory data
ARCH Venture Partners stages, portfolio and investment profile
Chicago-based life-sciences specialist that co-founds and funds seed through growth-stage biotech and deep-science companies, often originating companies directly from academic research.
Keep track of ARCH Venture Partners
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$1M–$10M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Seed, Series A
Participates: Seed, Series A, Series B+
Sector focus
biotech-life-sciences
Geography
Chicago, IL
Founded 1986
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
15
Linked startup profiles
Latest fund vehicle
Not recorded
Vehicle name, size, and vintage are not yet structured.
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Portfolio companies we track
Startups in our directory that list ARCH Venture Partners as an investor (15 total).
- Amber RNA-based multi-kilobase gene editing platform for diseases with high allelic diversity.
- Curie.Bio Biotech VC/accelerator pairing $5–15M seed checks with embedded drug-discovery services.
- EQRx Biotech that licensed and developed lower-cost branded cancer drugs before winding down after Revolution Medicines acquisition.
- Erasca Clinical-stage oncology company developing therapies that shut down multiple cancer growth pathways simultaneously.
- Gate Bio Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.
- Gate Bioscience Biotech developing oral Molecular Gate medicines that eliminate disease-causing proteins.
- Happy Health FDA-cleared smart ring and physician-guided platform for at-home sleep apnea diagnosis and continuous home care.
- Insitro ML-driven drug discovery platform applying large-scale biology data to identify novel therapeutics.
- Maze Therapeutics Clinical-stage biotech using human genetics to develop precision small-molecule medicines.
- Ollin Bio Clinical-stage retina biotech advancing OLN324, a VEGF/Ang2 bispecific for DME and wet AMD.
- Oratomic Neutral-atom quantum computing company pursuing a fault-tolerant utility-scale machine.
- Orbital Therapeutics RNA medicines platform acquired by Bristol Myers Squibb for $1.5B in 2025.
- Prometheus Physical-AI company building an "artificial general engineer" to automate design and manufacturing of complex hardware.
- ROME Therapeutics Biotech targeting the genomic repeatome for cancer and autoimmune disease.
- Soufflé Therapeutics Receptor-targeted RNA medicines designed to reach tissues beyond the liver.
Related investment articles
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.